Global Blood Therapeutics Company Profile

02:04 EDT 20th March 2018 | BioPortfolio

Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and genetic disorders for which there are currently no available cures and only extremely limited therapeutic options. The company’s SHAPE Platform enables the discovery and development of oral, small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits. Global Blood Therapeutics’ approach combines the most advanced computational biology and protein-ligand modeling with medicinal chemistry and empiric screening capabilities focused on allosteric modulation, while leveraging its team’s world-leading expertise in blood biology and proven success in drug discovery and development. Global Blood Therapeutics is a private company launched in 2012 by Third Rock Ventures with an experienced leadership team and renowned scientific founders. For more information, please visit

News Articles [2362 Associated News Articles listed on BioPortfolio]

Bay Area's Global Blood Therapeutics Terminates Lung Disease Program

Global Blood Therapeutics announced it is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).

Global Blood Therapeutics Stock Breaks Out, These Are the Implications

GBT Stock: Higher Prices Are Now in Development It didn't take long to vindicate my bullish stance on Global Blood Therapeutics Inc (NASDAQ:GBT) stock, because the same day my report, "Eyeing These...

Follow-on funding brings in $100M for Global Blood Therapeutics

A follow-on funding round brought in $100 million for Global Blood Therapeutics, which has an ongoing late-stage study of GBT -More- 

Global Blood reports on progress of Phase III study for sickle cell treatment

Upon the recommendation of an independent Data and Safety Monitoring Board, Global Blood Therapeutics' late-stage HOPE trial  -More- 

Global Blood nets $240.8mm through public stock offering

Global Blood Therapeutics Inc. netted $240.8mm through a public offering of 4.6mm common shares (including the overallotment) at $54. The company is developing treatments for blood-based diseases, and...

Global Blood Therapeutics Discontinues Development of Idiopathic Pulmonary Fibrosis Program

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the discontinuation of its GBT440 program for the treatment of id...

Follow-on funding raises $216M for Global Blood

A follow-on funding brought in $216 million for sickle cell company Global Blood Therapeutics, which has ongoing Phase III an -More- 

Global Blood Therapeutics to terminate studies of idiopathic pulmonary fibrosis program

Global Blood Therapeutics (GBT) has decided to terminate the GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF).

PubMed Articles [3318 Associated PubMed Articles listed on BioPortfolio]

Impact of Perioperative Blood Transfusion on Survival Among Women With Breast Cancer: Potential Benefits of Blood-Saving Agent Desmopressin Use During Surgery.

Assessment of relationship of ABO blood groups among tobacco induced oral cancer patients of Kanpur Population, Uttar Pradesh.

The possibility of association between ABO blood groups and malignancy was first discussed by Anderson DE & Haas C. The association between blood group and oral cancer is least explored and hence this...

Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

Cerebral blood flow velocity and autoregulation in paediatric patients following a global hypoxic-ischaemic insult.

To describe the cerebral blood flow velocity pattern and investigate cerebral autoregulation using transcranial Doppler ultrasonography (TCD) following a global hypoxic-ischaemic (HI) event in childre...

Short-Term Blood Pressure Responses to Ambient Fine Particulate Matter Exposures at the Extremes of Global Air Pollution Concentrations.

Fine particulate matter (PM2.5) air pollution is a leading cause of global cardiovascular mortality. A key mechanism may be PM2.5-induced blood pressure (BP) elevations. Whether consistent prohyperten...

Clinical Trials [4063 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Global Congestive Heart Failure Registry

Heart failure (HF) is a major health problem worldwide but there is no global HF study that documents demographics, socioeconomic and clinical factors, diagnostic and management patterns, ...

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Cryo AF Global Registry

Cryo AF Global Registry a prospective, global, multi-center, observational Post-Market Registry

Companies [2646 Associated Companies listed on BioPortfolio]

Global Blood Therapeutics

Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and genetic...


For more than 30 years, Haemonetics has been a global leader in blood processing technology. The Company has two families of products:Donor Products - These products are marketed to the blood donation...

Synthetic Blood International, Inc

Synthetic Blood International, Inc. (OTC BB: SYBD) is a cutting edge biomedical product development company specializing in creating innovative pharmaceuticals and medical devices in the fields of oxy...

ZymeQuest Incorporated

ZymeQuest, a development stage company, is the global leader in the discovery, development and commercialization of enzymatic blood conversion products for use in blood transfusion medicine. Our enzym...


CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, who...

More Information about "Global Blood Therapeutics" on BioPortfolio

We have published hundreds of Global Blood Therapeutics news stories on BioPortfolio along with dozens of Global Blood Therapeutics Clinical Trials and PubMed Articles about Global Blood Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global Blood Therapeutics Companies in our database. You can also find out about relevant Global Blood Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Corporate Database Quicklinks

Searches Linking to this Company Record